VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board

(Image credit: AdobeStock/Rawpixel.com)

VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also a professor of medicine (immunology and rheumatology) and professor of pediatrics at Stanford.¹

Among Nguyen’s notable work, he serves as principal investigator on clinical trials sponsored by the National Eye Institute and other organizations for macular edema, neovascular AMD, and ocular inflammatory and uveitic diseases. Nguyen was among the first clinician scientists to evaluate the safety and efficacy of aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME). This research became the foundation for subsequent trials leading to FDA approval of anti-VEGF therapy for retinal vascular diseases. He also led other trials, including READ-2, READ-3, and iDEAL studies for diabetic macular edema and SAVE, SAVE-2, STOP-UVEITIS, SATURN, ACTHAR, and ATLAS, and recently LEOPARD and LION studies for uveitis and ocular inflammatory diseases.¹

According to the news release¹ from VivaVision Biotech, Nguyen received both BS and MSc in Molecular Biophysics and Biochemistry from Yale and MD from the University of Pennsylvania Perelman School of Medicine. He completed his internship in Internal Medicine at the Massachusetts General Hospital and residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Nguyen also obtained fellowships in Uveitis as well as Vitreoretinal Surgery at the Massachusetts Eye and Ear Infirmary, and Ocular Immunology at the Wilmer Eye Institute, Johns Hopkins University.

Nguyen an active member of several notable societies and is serving as the current President of the International Ocular Inflammation Society, which is the largest society in the world devoted to ocular inflammation.¹

In the press release¹, the company also quoted Dr. Wang Shen, Founder and Chief Executive Officer of VivaVision Biotech, on the news of this appointment, who said, "We are very honored to welcome Professor Quan Dong Nguyen as a member of VivaVision Biotech's Scientific Advisory Board (SAB). Professor Quan Dong Nguyen's expertise and extensive experience in diabetic/uveitis-related macular edema, neovascular age-related macular degeneration (AMD), and intraocular inflammatory diseases will help VivaVision to further its innovative pipeline. In particular, we look forward to collaborating with Professor Quan Dong Nguyen on our dual JAK1/TYK2 inhibitor VVN461 (an ophthalmic solution) and VVN481 (a suspension for suprachoroidal injection). VivaVision will continue to strengthen its capabilities in R&D innovation, advance its pipeline both in China and abroad, and establish ourselves as a global leader in ophthalmic drug discovery."

What you should know about VivaVision Biotech

Founded in 2016, VivaVision Biotech is a clinical-stage pharmaceutical company dedicated to advance first-in-class and best-in-class therapies for ocular diseases. The company's leading pipeline assets include:

• VVN461: non-steroidal dual JAK1/TYK2 immunomodulator for post-operative inflammation after cataract surgery and non-infectious anterior uveitis.
• VVN001: an investigational treatment for dry eye disease.
• VVN1901: a therapy for neurotrophic keratitis
• VVN481: a non-steroidal dual JAK1/TYK2 inhibitor for suprachoroidal injection to treat posterior/pan-uveitis and posterior inflammatory diseases¹

Reference:

1.VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology. VivaVision Biotech. News Release. August 12, 2025. Accessed August 18, 2025. https://www.morningstar.com/news/pr-newswire/20250812cn45360/vivavision-strengthens-scientific-advisory-board-with-a-world-renowned-expert-in-ophthalmology